1. At a Glance – The Most Confusing Biotech in the Bazaar
Market Cap: ₹101 Cr.
Current Price: ₹78
Book Value: ₹6.42
Price to Book: 12.1x
ROCE: 51.6%
ROE: 51.6%
Debt: ₹0 Cr
Q3 FY26 Sales: ₹0.00 Cr
Q3 FY26 PAT: -₹0.03 Cr
3-Month Return: -48.1%
1-Year Return: 307%
Let me repeat that slowly.
This is a ₹101 crore company. With zero quarterly revenue.
Yet it trades at 12x book value.
And it delivered 307% return in one year.
Ladies and gentlemen, welcome to Genesis IBRC — the biotech company where the stock price does CrossFit but revenue does meditation.
Latest quarterly result (Q3 FY26) shows zero sales and a net loss of ₹3.18 lakh. But somehow the return on capital employed is 51.6%.
How?
Don’t worry. We’re going to unpack this mystery like a forensic accountant who also watches crime thrillers on Netflix.
Curious already?
Good.
2. Introduction – The Biotech That Forgot to Sell
Genesis IBRC India Ltd was incorporated in 1992 and is in the business of biotechnology.
On paper, it sounds exciting.
Aquaculture probiotics.
Water sanitizers.
Soil probiotics.
Vibrio controllers in shrimp culture.
Very science-heavy. Very marine-ecosystem-friendly. Very “we use lab coats and microscopes.”
But here’s the twist.
In FY21, the company generated no revenue. Not from operations. Not from other income.
And if you look at recent quarters, revenue continues to play hide and seek.
So what exactly is going on?
This company feels less like a biotech manufacturer and more like a corporate transformation series:
- Promoter reclassification
- Open offer at ₹7
- Board reshuffle
- New MD
- New CFO
- Preferential allotment of ₹40.25 crore
- Proposed name change
You see the pattern?
This isn’t just a business story. It’s a management reshuffle drama with a biotech backdrop.
And when a stock rises 307% in one year without revenue backing it, you have to ask:
Is this a turnaround in progress?
Or just a market mood swing?
Let’s investigate.
3. Business Model – WTF Do They Even Do?
Officially, Genesis IBRC operates in biotechnology.
Products include:
- Aquaculture probiotics
- Aqua feed supplements
- Water sanitizers
- Soil probiotics
- Shrimp vibrio controllers
Basically, if you’re a shrimp farmer and your pond water looks suspicious, Genesis says, “We’ve got gel for that.”
They offer:
- Proteomix Protein Balanced Gel
- Yuccagen Ammonia Controller
- Growfast Gen Single Cell Protein
- Progutgen Aquaculture Gut Probiotic
- Rhodogen PS Water Probiotic
Sounds impressive, right?
Now let’s look at sales.
Recent quarters show ₹0.00 crore revenue.
So either:
- The biotech lab is under maintenance.
- They’re in transition.
- Or the real action isn’t in probiotics.
Here’s what we do know from announcements:
- January 2026: Open offer at ₹7 per share.
- Acquirers now hold 62.08%.
- Board reconstituted.
- New MD appointed.
